GoodRx Holdings (GDRX) Net Cash Flow (2019 - 2026)

GoodRx Holdings has disclosed Net Cash Flow across 8 years of filings, most recently posting -$26.1 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$26.1 million, up 82.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$65.3 million (up 71.9% YoY), and the FY2025 annual result was -$186.5 million, up 16.71% from the prior year.
• Net Cash Flow came in at -$26.1 million for Q1 2026 at GoodRx Holdings, down from -$11.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $32.9 million in Q3 2023 to a low of -$147.4 million in Q1 2025.
• The 5-year median for Net Cash Flow is -$11.7 million (2025), against an average of -$41.5 million.
• Across the five-year window, Net Cash Flow jumped 1976.68% in 2023 and slumped 3655.01% in 2024, its largest moves.
• GoodRx Holdings' Net Cash Flow stood at $28.4 million in 2022, then plunged by 532.04% to -$122.6 million in 2023, then surged by 120.04% to $24.6 million in 2024, then sank by 147.66% to -$11.7 million in 2025, then tumbled by 122.99% to -$26.1 million in 2026.
• The last three Net Cash Flow figures came in at -$26.1 million (Q1 2026), -$11.7 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.